Immunovant, Inc. (IMVT) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2026 | $104.42M | +51.8% |
| 2025 | $68.78M | +41.5% |
| 2024 | $48.61M | +12.1% |
| 2023 | $43.34M | -5.2% |
| 2022 | $45.74M | +117.7% |
| 2021 | $21.01M | +37.2% |
| 2020 | $15.32M | +136.1% |
| 2019 | $6.49M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2026 | $104.42M | +51.8% |
| 2025 | $68.78M | +41.5% |
| 2024 | $48.61M | +12.1% |
| 2023 | $43.34M | -5.2% |
| 2022 | $45.74M | +117.7% |
| 2021 | $21.01M | +37.2% |
| 2020 | $15.32M | +136.1% |
| 2019 | $6.49M | — |